IV vs. IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: A feasibility study

Souvik Sen, David Y. Huang, Omid Akhavan, Susan Wilson, Piero Verro, Sten Solander

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background and Aims: Studies suggest that stroke patients with thrombus in a major cerebral vessel respond less favorably to intravenous (IV) thrombolysis. The purpose of this study was to test the feasibility of a protocol comparing IV versus intra-arterial (IA) recombinant tissue plasminogen activator (TPA) in an acute ischemic stroke with major vessel occlusion. Methods: Consecutive ischemic stroke patients presenting <3 h from symptom onset with major vessel occlusion on CT angiogram (CTA) were randomly assigned to IV TPA (per NINDS protocol) or IA TPA (22 mg over 2 h). Demographics, times to presentation and thrombolysis, presenting NIH stroke scale (NIHSS) and 90-day NIHSS, Barthel Index, and modified Rankin Scale were recorded. CT-scans at 24-h were reviewed for presence of hemorrhage. Recanalization was determined by post-procedure MR angiograms, which are obtained the day after thrombolytic therapy. Results: Seven patients (median NIHSS = 16) were randomized to IV (N = 4) or IA (N = 3) TPA. There were no significant differences in the presentation NIHSS, time to presentation, or time to treatment between the two groups. Hemorrhage was noted in one patient in the IA group (asymptomatic) and one patient in the IV group (symptomatic). Recanalization was seen in all patients treated with IA TPA and none treated with IV TPA (P = 0.03, Fisher's Exact test). Conclusions: We found that it is feasible to conduct a trial comparing IV vs. IA TPA in ischemic stroke patients with major vessel occlusion presenting <3 h from onset. Patients treated with IA TPA showed a trend toward higher rate of recanalization. A larger trial may be designed to test safety and effectiveness of IA TPA in this specific group of stroke patients.

Original languageEnglish (US)
Pages (from-to)76-81
Number of pages6
JournalNeurocritical Care
Volume11
Issue number1
DOIs
StatePublished - Aug 2009

Fingerprint

Feasibility Studies
Tissue Plasminogen Activator
Stroke
Angiography
National Institute of Neurological Disorders and Stroke
Hemorrhage
Thrombolytic Therapy
Thrombosis
Demography
Safety

Keywords

  • CT angiogram
  • Intra-arterial
  • Stroke
  • Thrombolysis

ASJC Scopus subject areas

  • Clinical Neurology
  • Critical Care and Intensive Care Medicine

Cite this

IV vs. IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion : A feasibility study. / Sen, Souvik; Huang, David Y.; Akhavan, Omid; Wilson, Susan; Verro, Piero; Solander, Sten.

In: Neurocritical Care, Vol. 11, No. 1, 08.2009, p. 76-81.

Research output: Contribution to journalArticle

Sen, Souvik ; Huang, David Y. ; Akhavan, Omid ; Wilson, Susan ; Verro, Piero ; Solander, Sten. / IV vs. IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion : A feasibility study. In: Neurocritical Care. 2009 ; Vol. 11, No. 1. pp. 76-81.
@article{24f7ec37671c4db782c510e65523296e,
title = "IV vs. IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: A feasibility study",
abstract = "Background and Aims: Studies suggest that stroke patients with thrombus in a major cerebral vessel respond less favorably to intravenous (IV) thrombolysis. The purpose of this study was to test the feasibility of a protocol comparing IV versus intra-arterial (IA) recombinant tissue plasminogen activator (TPA) in an acute ischemic stroke with major vessel occlusion. Methods: Consecutive ischemic stroke patients presenting <3 h from symptom onset with major vessel occlusion on CT angiogram (CTA) were randomly assigned to IV TPA (per NINDS protocol) or IA TPA (22 mg over 2 h). Demographics, times to presentation and thrombolysis, presenting NIH stroke scale (NIHSS) and 90-day NIHSS, Barthel Index, and modified Rankin Scale were recorded. CT-scans at 24-h were reviewed for presence of hemorrhage. Recanalization was determined by post-procedure MR angiograms, which are obtained the day after thrombolytic therapy. Results: Seven patients (median NIHSS = 16) were randomized to IV (N = 4) or IA (N = 3) TPA. There were no significant differences in the presentation NIHSS, time to presentation, or time to treatment between the two groups. Hemorrhage was noted in one patient in the IA group (asymptomatic) and one patient in the IV group (symptomatic). Recanalization was seen in all patients treated with IA TPA and none treated with IV TPA (P = 0.03, Fisher's Exact test). Conclusions: We found that it is feasible to conduct a trial comparing IV vs. IA TPA in ischemic stroke patients with major vessel occlusion presenting <3 h from onset. Patients treated with IA TPA showed a trend toward higher rate of recanalization. A larger trial may be designed to test safety and effectiveness of IA TPA in this specific group of stroke patients.",
keywords = "CT angiogram, Intra-arterial, Stroke, Thrombolysis",
author = "Souvik Sen and Huang, {David Y.} and Omid Akhavan and Susan Wilson and Piero Verro and Sten Solander",
year = "2009",
month = "8",
doi = "10.1007/s12028-009-9204-1",
language = "English (US)",
volume = "11",
pages = "76--81",
journal = "Neurocritical Care",
issn = "1541-6933",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - IV vs. IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion

T2 - A feasibility study

AU - Sen, Souvik

AU - Huang, David Y.

AU - Akhavan, Omid

AU - Wilson, Susan

AU - Verro, Piero

AU - Solander, Sten

PY - 2009/8

Y1 - 2009/8

N2 - Background and Aims: Studies suggest that stroke patients with thrombus in a major cerebral vessel respond less favorably to intravenous (IV) thrombolysis. The purpose of this study was to test the feasibility of a protocol comparing IV versus intra-arterial (IA) recombinant tissue plasminogen activator (TPA) in an acute ischemic stroke with major vessel occlusion. Methods: Consecutive ischemic stroke patients presenting <3 h from symptom onset with major vessel occlusion on CT angiogram (CTA) were randomly assigned to IV TPA (per NINDS protocol) or IA TPA (22 mg over 2 h). Demographics, times to presentation and thrombolysis, presenting NIH stroke scale (NIHSS) and 90-day NIHSS, Barthel Index, and modified Rankin Scale were recorded. CT-scans at 24-h were reviewed for presence of hemorrhage. Recanalization was determined by post-procedure MR angiograms, which are obtained the day after thrombolytic therapy. Results: Seven patients (median NIHSS = 16) were randomized to IV (N = 4) or IA (N = 3) TPA. There were no significant differences in the presentation NIHSS, time to presentation, or time to treatment between the two groups. Hemorrhage was noted in one patient in the IA group (asymptomatic) and one patient in the IV group (symptomatic). Recanalization was seen in all patients treated with IA TPA and none treated with IV TPA (P = 0.03, Fisher's Exact test). Conclusions: We found that it is feasible to conduct a trial comparing IV vs. IA TPA in ischemic stroke patients with major vessel occlusion presenting <3 h from onset. Patients treated with IA TPA showed a trend toward higher rate of recanalization. A larger trial may be designed to test safety and effectiveness of IA TPA in this specific group of stroke patients.

AB - Background and Aims: Studies suggest that stroke patients with thrombus in a major cerebral vessel respond less favorably to intravenous (IV) thrombolysis. The purpose of this study was to test the feasibility of a protocol comparing IV versus intra-arterial (IA) recombinant tissue plasminogen activator (TPA) in an acute ischemic stroke with major vessel occlusion. Methods: Consecutive ischemic stroke patients presenting <3 h from symptom onset with major vessel occlusion on CT angiogram (CTA) were randomly assigned to IV TPA (per NINDS protocol) or IA TPA (22 mg over 2 h). Demographics, times to presentation and thrombolysis, presenting NIH stroke scale (NIHSS) and 90-day NIHSS, Barthel Index, and modified Rankin Scale were recorded. CT-scans at 24-h were reviewed for presence of hemorrhage. Recanalization was determined by post-procedure MR angiograms, which are obtained the day after thrombolytic therapy. Results: Seven patients (median NIHSS = 16) were randomized to IV (N = 4) or IA (N = 3) TPA. There were no significant differences in the presentation NIHSS, time to presentation, or time to treatment between the two groups. Hemorrhage was noted in one patient in the IA group (asymptomatic) and one patient in the IV group (symptomatic). Recanalization was seen in all patients treated with IA TPA and none treated with IV TPA (P = 0.03, Fisher's Exact test). Conclusions: We found that it is feasible to conduct a trial comparing IV vs. IA TPA in ischemic stroke patients with major vessel occlusion presenting <3 h from onset. Patients treated with IA TPA showed a trend toward higher rate of recanalization. A larger trial may be designed to test safety and effectiveness of IA TPA in this specific group of stroke patients.

KW - CT angiogram

KW - Intra-arterial

KW - Stroke

KW - Thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=70349309347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349309347&partnerID=8YFLogxK

U2 - 10.1007/s12028-009-9204-1

DO - 10.1007/s12028-009-9204-1

M3 - Article

C2 - 19277904

AN - SCOPUS:70349309347

VL - 11

SP - 76

EP - 81

JO - Neurocritical Care

JF - Neurocritical Care

SN - 1541-6933

IS - 1

ER -